ID   WNK1_HUMAN              Reviewed;        2382 AA.
AC   Q9H4A3; A1L4B0; C5HTZ5; C5HTZ6; C5HTZ7; H6WZW3; O15052; P54963; Q4VBX9;
AC   Q6IFS5; Q86WL5; Q8N673; Q96CZ6; Q9P1S9;
DT   02-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   12-OCT-2022, entry version 215.
DE   RecName: Full=Serine/threonine-protein kinase WNK1 {ECO:0000305};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:10660600};
DE   AltName: Full=Erythrocyte 65 kDa protein;
DE            Short=p65;
DE   AltName: Full=Kinase deficient protein;
DE   AltName: Full=Protein kinase lysine-deficient 1 {ECO:0000312|HGNC:HGNC:14540};
DE   AltName: Full=Protein kinase with no lysine 1 {ECO:0000303|PubMed:11571656};
DE            Short=hWNK1;
GN   Name=WNK1 {ECO:0000312|HGNC:HGNC:14540};
GN   Synonyms=HSN2 {ECO:0000303|PubMed:15060842}, KDP, KIAA0344
GN   {ECO:0000312|EMBL:BAA20802.2}, PRKWNK1 {ECO:0000312|HGNC:HGNC:14540};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:CAC15059.1};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, CHROMOSOMAL
RP   LOCATION, AND VARIANTS PRO-1056; SER-1506 AND ILE-1808.
RC   TISSUE=Heart {ECO:0000312|EMBL:CAC15059.1};
RX   PubMed=11571656; DOI=10.1038/sj.onc.1204726;
RA   Verissimo F., Jordan P.;
RT   "WNK kinases, a novel protein kinase subfamily in multi-cellular
RT   organisms.";
RL   Oncogene 20:5562-5569(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), ALTERNATIVE SPLICING, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Neuron;
RX   PubMed=22701532; DOI=10.1371/journal.pone.0037751;
RA   Vidal-Petiot E., Cheval L., Faugeroux J., Malard T., Doucet A.,
RA   Jeunemaitre X., Hadchouel J.;
RT   "A new methodology for quantification of alternatively spliced exons
RT   reveals a highly tissue-specific expression pattern of WNK1 isoforms.";
RL   PLoS ONE 7:E37751-E37751(2012).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-1056; SER-1506 AND
RP   ILE-1808.
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [5] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-668 (ISOFORMS 1/2), FUNCTION, CATALYTIC
RP   ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=10660600; DOI=10.1074/jbc.275.6.4311;
RA   Moore T.M., Garg R., Johnson C., Coptcoat M.J., Ridley A.J., Morris J.D.H.;
RT   "PSK, a novel STE20-like kinase derived from prostatic carcinoma that
RT   activates the JNK MAPK pathway and regulates actin cytoskeletal
RT   organisation.";
RL   J. Biol. Chem. 275:4311-4322(2000).
RN   [6] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 69-2382 (ISOFORM 2), AND VARIANTS
RP   PRO-1056 AND SER-1506.
RC   TISSUE=Brain {ECO:0000312|EMBL:BAA20802.2};
RX   PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [7] {ECO:0000305}
RP   SEQUENCE REVISION TO N-TERMINUS.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [8]
RP   PROTEIN SEQUENCE OF 163-175, AND GLYCOSYLATION.
RX   PubMed=2507249; DOI=10.1002/9780470513828.ch7;
RA   Hart G.W., Haltiwanger R.S., Holt G.D., Kelly W.G.;
RT   "Nucleoplasmic and cytoplasmic glycoproteins.";
RL   Ciba Found. Symp. 145:102-118(1989).
RN   [9] {ECO:0000305}
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (N-TERMINUS OF ISOFORM 3), ALTERNATIVE
RP   PROMOTER USAGE, ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney {ECO:0000269|PubMed:14645531};
RX   PubMed=14645531; DOI=10.1128/mcb.23.24.9208-9221.2003;
RA   Delaloy C., Lu J., Houot A.-M., Disse-Nicodeme S., Gasc J.-M., Corvol P.,
RA   Jeunemaitre X.;
RT   "Multiple promoters in the WNK1 gene: one controls expression of a kidney-
RT   specific kinase-defective isoform.";
RL   Mol. Cell. Biol. 23:9208-9221(2003).
RN   [10] {ECO:0000305}
RP   PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1/4/5).
RC   TISSUE=Placenta {ECO:0000269|PubMed:15489334};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   IDENTIFICATION (ISOFORMS 4/5), FUNCTION, AND INVOLVEMENT IN HSAN2A.
RX   PubMed=15060842; DOI=10.1086/420795;
RA   Lafreniere R.G., MacDonald M.L.E., Dube M.-P., MacFarlane J.,
RA   O'Driscoll M., Brais B., Meilleur S., Brinkman R.R., Dadivas O., Pape T.,
RA   Platon C., Radomski C., Risler J., Thompson J., Guerra-Escobio A.-M.,
RA   Davar G., Breakefield X.O., Pimstone S.N., Green R., Pryse-Phillips W.,
RA   Goldberg Y.P., Younghusband H.B., Hayden M.R., Sherrington R.,
RA   Rouleau G.A., Samuels M.E.;
RT   "Identification of a novel gene (HSN2) causing hereditary sensory and
RT   autonomic neuropathy type II through the study of Canadian genetic
RT   isolates.";
RL   Am. J. Hum. Genet. 74:1064-1073(2004).
RN   [12] {ECO:0000305}
RP   INVOLVEMENT IN PHA2C.
RX   PubMed=11498583; DOI=10.1126/science.1062844;
RA   Wilson F.H., Disse-Nicodeme S., Choate K.A., Ishikawa K.,
RA   Nelson-Williams C., Desitter I., Gunel M., Milford D.V., Lipkin G.W.,
RA   Achard J.-M., Feely M.P., Dussol B., Berland Y., Unwin R.J., Mayan H.,
RA   Simon D.B., Farfel Z., Jeunemaitre X., Lifton R.P.;
RT   "Human hypertension caused by mutations in WNK kinases.";
RL   Science 293:1107-1112(2001).
RN   [13]
RP   INVOLVEMENT IN HSAN2A.
RX   PubMed=15911806; DOI=10.1212/01.wnl.0000161849.29944.43;
RA   Roddier K., Thomas T., Marleau G., Gagnon A.M., Dicaire M.J., St Denis A.,
RA   Gosselin I., Sarrazin A.M., Larbrisseau A., Lambert M., Vanasse M.,
RA   Gaudet D., Rouleau G.A., Brais B.;
RT   "Two mutations in the HSN2 gene explain the high prevalence of HSAN2 in
RT   French Canadians.";
RL   Neurology 64:1762-1767(2005).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2002 AND SER-2032, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1261, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [16]
RP   ALTERNATIVE SPLICING (ISOFORMS 4 AND 5), AND INVOLVEMENT IN HSAN2A.
RX   PubMed=18521183; DOI=10.1172/jci34088;
RA   Shekarabi M., Girard N., Riviere J.B., Dion P., Houle M., Toulouse A.,
RA   Lafreniere R.G., Vercauteren F., Hince P., Laganiere J., Rochefort D.,
RA   Faivre L., Samuels M., Rouleau G.A.;
RT   "Mutations in the nervous system--specific HSN2 exon of WNK1 cause
RT   hereditary sensory neuropathy type II.";
RL   J. Clin. Invest. 118:2496-2505(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-1261; SER-2011;
RP   SER-2012; SER-2027; SER-2029 AND SER-2032, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1978, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-1261; SER-1978;
RP   SER-2032 AND SER-2121, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2027; SER-2029 AND SER-2032,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [24]
RP   UBIQUITINATION BY KLHL2.
RX   PubMed=23838290; DOI=10.1016/j.bbrc.2013.06.104;
RA   Takahashi D., Mori T., Wakabayashi M., Mori Y., Susa K., Zeniya M.,
RA   Sohara E., Rai T., Sasaki S., Uchida S.;
RT   "KLHL2 interacts with and ubiquitinates WNK kinases.";
RL   Biochem. Biophys. Res. Commun. 437:457-462(2013).
RN   [25]
RP   INTERACTION WITH KLHL3.
RX   PubMed=23387299; DOI=10.1042/bj20121903;
RA   Ohta A., Schumacher F.R., Mehellou Y., Johnson C., Knebel A.,
RA   Macartney T.J., Wood N.T., Alessi D.R., Kurz T.;
RT   "The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome
RT   interacts with and ubiquitylates WNK isoforms: disease-causing mutations in
RT   KLHL3 and WNK4 disrupt interaction.";
RL   Biochem. J. 451:111-122(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-167; SER-174;
RP   SER-1261; SER-2029; SER-2032; SER-2370 AND SER-2372, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [27]
RP   UBIQUITINATION, AND INTERACTION WITH KLHL3.
RX   PubMed=23576762; DOI=10.1073/pnas.1304592110;
RA   Shibata S., Zhang J., Puthumana J., Stone K.L., Lifton R.P.;
RT   "Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via
RT   ubiquitination and degradation of WNK4.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:7838-7843(2013).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-167; SER-174; SER-1978 AND
RP   SER-2027, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [29] {ECO:0007744|PDB:4PWN}
RP   X-RAY CRYSTALLOGRAPHY (1.84 ANGSTROMS) OF 210-482.
RX   PubMed=24803536; DOI=10.1126/scisignal.2005050;
RA   Piala A.T., Moon T.M., Akella R., He H., Cobb M.H., Goldsmith E.J.;
RT   "Chloride sensing by WNK1 involves inhibition of autophosphorylation.";
RL   Sci. Signal. 7:RA41-RA41(2014).
RN   [30] {ECO:0007744|PDB:5TF9}
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 206-483 IN COMPLEX WITH ATP AND
RP   ALLOSTERIC INHIBITOR.
RX   PubMed=27712055; DOI=10.1021/acschembio.6b00511;
RA   Yamada K., Zhang J.H., Xie X., Reinhardt J., Xie A.Q., LaSala D., Kohls D.,
RA   Yowe D., Burdick D., Yoshisue H., Wakai H., Schmidt I., Gunawan J.,
RA   Yasoshima K., Yue Q.K., Kato M., Mogi M., Idamakanti N., Kreder N.,
RA   Drueckes P., Pandey P., Kawanami T., Huang W., Yagi Y.I., Deng Z.,
RA   Park H.M.;
RT   "Discovery and characterization of allosteric WNK kinase inhibitors.";
RL   ACS Chem. Biol. 11:3338-3346(2016).
RN   [31]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-1199 AND GLU-1799.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [32]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-141; VAL-149; GLN-419; THR-509;
RP   GLY-527; ILE-665; ALA-674; ARG-823; VAL-1546; GLU-1799; ILE-1808; LEU-1823;
RP   HIS-1957; CYS-2190; LEU-2362 AND TRP-2380.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase which plays an important role in the
CC       regulation of electrolyte homeostasis, cell signaling, survival, and
CC       proliferation. Acts as an activator and inhibitor of sodium-coupled
CC       chloride cotransporters and potassium-coupled chloride cotransporters
CC       respectively. Activates SCNN1A, SCNN1B, SCNN1D and SGK1. Controls
CC       sodium and chloride ion transport by inhibiting the activity of WNK4,
CC       by either phosphorylating the kinase or via an interaction between WNK4
CC       and the autoinhibitory domain of WNK1. WNK4 regulates the activity of
CC       the thiazide-sensitive Na-Cl cotransporter, SLC12A3, by
CC       phosphorylation. WNK1 may also play a role in actin cytoskeletal
CC       reorganization. Phosphorylates NEDD4L. Acts as a scaffold to inhibit
CC       SLC4A4, SLC26A6 as well as CFTR activities and surface expression,
CC       recruits STK39 which mediates the inhibition (By similarity).
CC       {ECO:0000250|UniProtKB:P83741, ECO:0000250|UniProtKB:Q9JIH7,
CC       ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:15060842}.
CC   -!- FUNCTION: [Isoform 3]: Dominant-negative regulator of the longer
CC       isoform 1. Does not have kinase activity, does not directly inhibit
CC       WNK4 and has no direct effect on sodium and chloride ion transport.
CC       Down-regulates sodium-chloride cotransporter activity indirectly by
CC       inhibiting isoform 1, it associates with isoform 1 and attenuates its
CC       kinase activity. In kidney, may play an important role regulating
CC       sodium and potassium balance. {ECO:0000250|UniProtKB:Q9JIH7}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:10660600};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:10660600};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10660600};
CC   -!- ACTIVITY REGULATION: By hypertonicity. Activation requires
CC       autophosphorylation of Ser-382, that may be regulated by calcium.
CC       Phosphorylation of Ser-378 also promotes increased activity.
CC       {ECO:0000250|UniProtKB:Q9JIH7}.
CC   -!- SUBUNIT: Interacts with SYT2 (By similarity). Interacts with WNK3 and
CC       WNK4 (By similarity). Interacts with KLHL3 (PubMed:23387299,
CC       PubMed:23576762). Isoform 3: Interacts with isoform 1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:23387299,
CC       ECO:0000269|PubMed:23576762}.
CC   -!- INTERACTION:
CC       Q9H4A3; O95747: OXSR1; NbExp=8; IntAct=EBI-457907, EBI-620853;
CC       Q9H4A3; P62136: PPP1CA; NbExp=2; IntAct=EBI-457907, EBI-357253;
CC       Q9H4A3; Q93009: USP7; NbExp=2; IntAct=EBI-457907, EBI-302474;
CC       Q9H4A3; P29101: Syt2; Xeno; NbExp=2; IntAct=EBI-457907, EBI-458017;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10660600}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=6;
CC         Comment=WNK1 is a complex 33-exons gene, in total 9 WNK1 exons are
CC         alternatively spliced, some expressed in a tissue-specific manner.
CC         Additional isoforms seems to exist.;
CC       Name=1 {ECO:0000269|PubMed:11571656}; Synonyms=L-WNK1;
CC         IsoId=Q9H4A3-1; Sequence=Displayed;
CC       Name=2 {ECO:0000303|PubMed:9205841};
CC         IsoId=Q9H4A3-2; Sequence=VSP_040269, VSP_050638;
CC       Name=3; Synonyms=KS-WNK1, Kidney-Specific;
CC         IsoId=Q9H4A3-4; Sequence=VSP_050634, VSP_050637;
CC       Name=4; Synonyms=Brain and spinal cord variant;
CC         IsoId=Q9H4A3-5; Sequence=VSP_040268;
CC       Name=5; Synonyms=Dorsal root ganglia and sciatic nerve variant, DRG and
CC       sciatic nerve variant;
CC         IsoId=Q9H4A3-6; Sequence=VSP_040267, VSP_040270;
CC       Name=6;
CC         IsoId=Q9H4A3-7; Sequence=VSP_040267, VSP_053767;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest levels observed in
CC       the testis, heart, kidney and skeletal muscle. Isoform 3 is kidney-
CC       specific and specifically expressed in the distal convoluted tubule
CC       (DCT) and connecting tubule (CNT) of the nephron.
CC       {ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:11571656,
CC       ECO:0000269|PubMed:14645531, ECO:0000269|PubMed:22701532}.
CC   -!- PTM: Autophosphorylation at Ser-382 is inhibited by intracellular
CC       calcium. {ECO:0000250|UniProtKB:Q9JIH7}.
CC   -!- PTM: May be O-glycosylated. {ECO:0000269|PubMed:2507249}.
CC   -!- PTM: Ubiquitinated in vitro by the BCR(KLHL3) complex and in vivo by a
CC       BCR(KLHL2) complex, leading to proteasomal degradation.
CC       {ECO:0000269|PubMed:23576762, ECO:0000269|PubMed:23838290}.
CC   -!- DISEASE: Pseudohypoaldosteronism 2C (PHA2C) [MIM:614492]: An autosomal
CC       dominant disorder characterized by severe hypertension, hyperkalemia,
CC       hyperchloremia, mild hyperchloremic metabolic acidosis in some cases,
CC       and correction of physiologic abnormalities by thiazide diuretics.
CC       {ECO:0000269|PubMed:11498583}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Neuropathy, hereditary sensory and autonomic, 2A (HSAN2A)
CC       [MIM:201300]: A form of hereditary sensory and autonomic neuropathy, a
CC       genetically and clinically heterogeneous group of disorders
CC       characterized by degeneration of dorsal root and autonomic ganglion
CC       cells, and by sensory and/or autonomic abnormalities. HSAN2A is an
CC       autosomal recessive disorder characterized by impairment of pain,
CC       temperature and touch sensation, onset of symptoms in infancy or early
CC       childhood, occurrence of distal extremity pathologies (paronychia,
CC       whitlows, ulcers, and Charcot joints), frequent amputations, sensory
CC       loss that affects all modalities of sensation (lower and upper limbs
CC       and perhaps the trunk as well), absence or diminution of tendon
CC       reflexes (usually in all limbs), minimal autonomic dysfunction, absence
CC       of sensory nerve action potentials, and virtual absence of myelinated
CC       fibers with decreased numbers of unmyelinated fibers in sural nerves.
CC       {ECO:0000269|PubMed:15060842, ECO:0000269|PubMed:15911806,
CC       ECO:0000269|PubMed:18521183}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 1]: Strong expression in dorsal root ganglia
CC       and spinal cord.
CC   -!- MISCELLANEOUS: [Isoform 3]: Kinase-defective isoform. Produced by
CC       alternative promoter usage and alternative splicing. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Contains the nervous system-specific exon
CC       HSN2. Produced by alternative splicing. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Contains the nervous system-specific exon
CC       HSN2. Produced by alternative splicing. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Contains the nervous system-specific exon
CC       HSN2. Produced by alternative splicing. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. WNK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- CAUTION: Was named WNK/'with no lysine(K)' because key residues for
CC       catalysis, including the lysine involved in ATP binding, are either not
CC       conserved or differ compared to the residues described in other kinase
CC       family proteins. {ECO:0000305|PubMed:27712055}.
CC   -!- CAUTION: HSN2 was originally thought to be an intronless gene lying
CC       within a WNK1 gene intron. It has been shown to be a nervous system-
CC       specific exon of WNK1 included in isoform 4 and isoform 5
CC       (PubMed:18521183). {ECO:0000305|PubMed:18521183}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-214 is the initiator in
CC       isoform 4 and isoform 5. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF31483.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the C-terminal part.; Evidence={ECO:0000305};
CC       Sequence=AAI30468.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC       Sequence=AAI30470.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC       Sequence=DAA04494.1; Type=Erroneous gene model prediction; Note=Includes 3' and 3' intronic sequences.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ296290; CAC15059.1; -; mRNA.
DR   EMBL; JQ358908; AEY99342.1; -; mRNA.
DR   EMBL; FJ515833; ACS13726.1; -; Genomic_DNA.
DR   EMBL; FJ515833; ACS13727.1; -; Genomic_DNA.
DR   EMBL; FJ515833; ACS13728.1; -; Genomic_DNA.
DR   EMBL; AC004765; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC004803; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF061944; AAF31483.1; ALT_SEQ; mRNA.
DR   EMBL; AB002342; BAA20802.2; -; mRNA.
DR   EMBL; AY231477; AAO46160.1; -; mRNA.
DR   EMBL; BC013629; AAH13629.2; -; mRNA.
DR   EMBL; BC130467; AAI30468.1; ALT_SEQ; mRNA.
DR   EMBL; BC130469; AAI30470.1; ALT_SEQ; mRNA.
DR   EMBL; BK004108; DAA04494.1; ALT_SEQ; Genomic_DNA.
DR   CCDS; CCDS73419.1; -. [Q9H4A3-5]
DR   CCDS; CCDS8506.1; -. [Q9H4A3-1]
DR   RefSeq; NP_001171914.1; NM_001184985.1. [Q9H4A3-6]
DR   RefSeq; NP_055638.2; NM_014823.2.
DR   RefSeq; NP_061852.3; NM_018979.3. [Q9H4A3-1]
DR   RefSeq; NP_998820.3; NM_213655.4. [Q9H4A3-5]
DR   RefSeq; XP_016875326.1; XM_017019837.1.
DR   RefSeq; XP_016875327.1; XM_017019838.1. [Q9H4A3-2]
DR   PDB; 4PWN; X-ray; 1.84 A; A=210-482.
DR   PDB; 5TF9; X-ray; 2.50 A; A/B=206-483.
DR   PDB; 5WDY; X-ray; 2.46 A; A/B=206-483.
DR   PDB; 5WE8; X-ray; 2.01 A; A/B=206-483.
DR   PDB; 6FBK; X-ray; 1.74 A; P=1247-1269.
DR   PDBsum; 4PWN; -.
DR   PDBsum; 5TF9; -.
DR   PDBsum; 5WDY; -.
DR   PDBsum; 5WE8; -.
DR   PDBsum; 6FBK; -.
DR   AlphaFoldDB; Q9H4A3; -.
DR   BMRB; Q9H4A3; -.
DR   SMR; Q9H4A3; -.
DR   BioGRID; 122403; 111.
DR   CORUM; Q9H4A3; -.
DR   DIP; DIP-32648N; -.
DR   ELM; Q9H4A3; -.
DR   IntAct; Q9H4A3; 91.
DR   MINT; Q9H4A3; -.
DR   BindingDB; Q9H4A3; -.
DR   ChEMBL; CHEMBL1075173; -.
DR   GuidetoPHARMACOLOGY; 2280; -.
DR   MoonDB; Q9H4A3; Predicted.
DR   GlyConnect; 484; 1 O-GlcNAc glycan.
DR   GlyGen; Q9H4A3; 39 sites, 2 O-linked glycans (39 sites).
DR   iPTMnet; Q9H4A3; -.
DR   MetOSite; Q9H4A3; -.
DR   PhosphoSitePlus; Q9H4A3; -.
DR   BioMuta; WNK1; -.
DR   DMDM; 296453029; -.
DR   EPD; Q9H4A3; -.
DR   jPOST; Q9H4A3; -.
DR   MassIVE; Q9H4A3; -.
DR   MaxQB; Q9H4A3; -.
DR   PaxDb; Q9H4A3; -.
DR   PeptideAtlas; Q9H4A3; -.
DR   PRIDE; Q9H4A3; -.
DR   ProteomicsDB; 80804; -. [Q9H4A3-1]
DR   ProteomicsDB; 80805; -. [Q9H4A3-2]
DR   ProteomicsDB; 80806; -. [Q9H4A3-4]
DR   ProteomicsDB; 80807; -. [Q9H4A3-5]
DR   ProteomicsDB; 80808; -. [Q9H4A3-6]
DR   Antibodypedia; 22083; 615 antibodies from 41 providers.
DR   DNASU; 65125; -.
DR   Ensembl; ENST00000315939.11; ENSP00000313059.6; ENSG00000060237.19. [Q9H4A3-1]
DR   Ensembl; ENST00000340908.9; ENSP00000341292.5; ENSG00000060237.19. [Q9H4A3-5]
DR   Ensembl; ENST00000530271.6; ENSP00000433548.3; ENSG00000060237.19. [Q9H4A3-7]
DR   Ensembl; ENST00000537687.5; ENSP00000444465.1; ENSG00000060237.19. [Q9H4A3-6]
DR   Ensembl; ENST00000675631.1; ENSP00000502415.1; ENSG00000060237.19. [Q9H4A3-4]
DR   GeneID; 65125; -.
DR   KEGG; hsa:65125; -.
DR   MANE-Select; ENST00000315939.11; ENSP00000313059.6; NM_018979.4; NP_061852.3.
DR   UCSC; uc001qio.4; human. [Q9H4A3-1]
DR   CTD; 65125; -.
DR   DisGeNET; 65125; -.
DR   GeneCards; WNK1; -.
DR   GeneReviews; WNK1; -.
DR   HGNC; HGNC:14540; WNK1.
DR   HPA; ENSG00000060237; Tissue enhanced (brain).
DR   MalaCards; WNK1; -.
DR   MIM; 201300; phenotype.
DR   MIM; 605232; gene.
DR   MIM; 614492; phenotype.
DR   neXtProt; NX_Q9H4A3; -.
DR   OpenTargets; ENSG00000060237; -.
DR   Orphanet; 970; Hereditary sensory and autonomic neuropathy type 2.
DR   Orphanet; 88940; Pseudohypoaldosteronism type 2C.
DR   PharmGKB; PA33782; -.
DR   VEuPathDB; HostDB:ENSG00000060237; -.
DR   eggNOG; KOG0584; Eukaryota.
DR   GeneTree; ENSGT00940000155474; -.
DR   InParanoid; Q9H4A3; -.
DR   OMA; PEPNGMT; -.
DR   OrthoDB; 27514at2759; -.
DR   PhylomeDB; Q9H4A3; -.
DR   TreeFam; TF315363; -.
DR   PathwayCommons; Q9H4A3; -.
DR   Reactome; R-HSA-2672351; Stimuli-sensing channels.
DR   SignaLink; Q9H4A3; -.
DR   SIGNOR; Q9H4A3; -.
DR   BioGRID-ORCS; 65125; 563 hits in 1133 CRISPR screens.
DR   ChiTaRS; WNK1; human.
DR   GeneWiki; WNK1; -.
DR   GenomeRNAi; 65125; -.
DR   Pharos; Q9H4A3; Tchem.
DR   PRO; PR:Q9H4A3; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q9H4A3; protein.
DR   Bgee; ENSG00000060237; Expressed in medial globus pallidus and 202 other tissues.
DR   ExpressionAtlas; Q9H4A3; baseline and differential.
DR   Genevisible; Q9H4A3; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016020; C:membrane; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0032991; C:protein-containing complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0019869; F:chloride channel inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0019902; F:phosphatase binding; IDA:UniProtKB.
DR   GO; GO:0019870; F:potassium channel inhibitor activity; IBA:GO_Central.
DR   GO; GO:0030295; F:protein kinase activator activity; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0004860; F:protein kinase inhibitor activity; IEA:UniProtKB-KW.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0055080; P:cation homeostasis; ISS:UniProtKB.
DR   GO; GO:0030644; P:cellular chloride ion homeostasis; IEA:Ensembl.
DR   GO; GO:1990869; P:cellular response to chemokine; IMP:BHF-UCL.
DR   GO; GO:0038116; P:chemokine (C-C motif) ligand 21 signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0050801; P:ion homeostasis; IBA:GO_Central.
DR   GO; GO:0006811; P:ion transport; ISS:UniProtKB.
DR   GO; GO:0097022; P:lymphocyte migration into lymph node; ISS:BHF-UCL.
DR   GO; GO:0033633; P:negative regulation of cell-cell adhesion mediated by integrin; IMP:BHF-UCL.
DR   GO; GO:0034260; P:negative regulation of GTPase activity; IMP:BHF-UCL.
DR   GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; IMP:BHF-UCL.
DR   GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IMP:BHF-UCL.
DR   GO; GO:0090188; P:negative regulation of pancreatic juice secretion; IEA:Ensembl.
DR   GO; GO:0010766; P:negative regulation of sodium ion transport; ISS:UniProtKB.
DR   GO; GO:0048666; P:neuron development; NAS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IMP:ARUK-UCL.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:FlyBase.
DR   GO; GO:1903288; P:positive regulation of potassium ion import across plasma membrane; IBA:GO_Central.
DR   GO; GO:2000651; P:positive regulation of sodium ion transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0010820; P:positive regulation of T cell chemotaxis; IMP:BHF-UCL.
DR   GO; GO:0055075; P:potassium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:1904062; P:regulation of cation transmembrane transport; IMP:ARUK-UCL.
DR   GO; GO:0002028; P:regulation of sodium ion transport; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; IEA:Ensembl.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; ISS:BHF-UCL.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR024678; Kinase_OSR1/WNK_CCT.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF12202; OSR1_C; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Alternative splicing;
KW   ATP-binding; Cytoplasm; Direct protein sequencing; Glycoprotein; Kinase;
KW   Neurodegeneration; Neuropathy; Nucleotide-binding; Phosphoprotein;
KW   Protein kinase inhibitor; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN           1..2382
FT                   /note="Serine/threonine-protein kinase WNK1"
FT                   /id="PRO_0000086819"
FT   DOMAIN          221..479
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..81
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          95..203
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          488..555
FT                   /note="Autoinhibitory domain"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JIH7"
FT   REGION          573..779
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1018..1041
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1053..1119
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1457..1476
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1733..1790
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1866..1948
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1994..2069
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2101..2196
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2332..2352
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..17
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        49..65
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        101..115
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        152..168
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        573..589
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        590..629
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        636..779
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1053..1092
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1096..1116
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1733..1748
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1871..1885
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1886..1906
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1922..1948
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2030..2062
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2133..2196
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        368
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JIH7"
FT   BINDING         231
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:27712055,
FT                   ECO:0007744|PDB:5TF9"
FT   BINDING         301..304
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:27712055,
FT                   ECO:0007744|PDB:5TF9"
FT   BINDING         351
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:27712055,
FT                   ECO:0007744|PDB:5TF9"
FT   MOD_RES         19
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         167
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         174
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         378
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JIH7"
FT   MOD_RES         382
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JIH7"
FT   MOD_RES         1261
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1978
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569"
FT   MOD_RES         2002
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983"
FT   MOD_RES         2011
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         2012
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         2027
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569"
FT   MOD_RES         2029
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         2032
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         2121
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         2270
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P83741"
FT   MOD_RES         2286
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P83741"
FT   MOD_RES         2370
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2372
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..407
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_050634"
FT   VAR_SEQ         408..437
FT                   /note="FGMCMLEMATSEYPYSECQNAAQIYRRVTS -> MDIKKKDFCSVFVIINSH
FT                   CCCCPQKDCINE (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_050637"
FT   VAR_SEQ         713
FT                   /note="V -> VPQSMAHPCGGTPTYPESQIFFPTIHERPVSFSPPPTCPPKVAISQR
FT                   RKSTSFLEAQTHHFQPLLRTVGQSLLPPGGSPTNWTPEAVVMLGTTASRVTGESCEIQV
FT                   HPMFEPSQVYSDYRPGLVLPEEAHYFIPQEAVYVAGVHYQARVAEQYEGIPYNSSVLSS
FT                   PMKQIPEQKPVQGGPTSSSVFEFPSGQAFLVGHLQNLRLDSGLGPGSPLSSISAPISTD
FT                   ATRLKFHPVFVPHSAPAVLTHNNESRSNCVFEFHVHTPSSSSGEGGGILPQRVYRNRQV
FT                   AVDLNQEELPPQSVGLHGYLQPVTEEKHNYHAPELTVSVVEPIGQNWPIGSPEYSSDSS
FT                   QITSSDPSDFQSPPPTGGAAAPFGSDVSMPFIHLPQTVLQESPLFFCFPQGTTSQQVLT
FT                   ASFSSGGSALHPQ (in isoform 5 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:22701532"
FT                   /id="VSP_040267"
FT   VAR_SEQ         714..1037
FT                   /note="AQGQSQGQPSSSSLTGVSSSQPIQHPQQQQGIQQTAPPQQTVQYSLSQTSTS
FT                   SEATTAQPVSQPQAPQVLPQVSAGKQLPVSQPVPTIQGEPQIPVATQPSVVPVHSGAHF
FT                   LPVGQPLPTPLLPQYPVSQIPISTPHVSTAQTGFSSLPITMAAGITQPLLTLASSATTA
FT                   AIPGVSTVVPSQLPTLLQPVTQLPSQVHPQLLQPAVQSMGIPANLGQAAEVPLSSGDVL
FT                   YQGFPPRLPPQYPGDSNIAPSSNVASVCIHSTVLSPPMPTEVLATPGYFPTVVQPYVES
FT                   NLLVPMGGVGGQVQVSQPGGSLAQAPTTSSQQAVLE -> PRRGRSMSVCVPIFLLLPL
FT                   CPASLPVLFHPTASTVCTSFSFPPPDCPEETFAEKLSKALESVLPMHSASQRKHRRSSL
FT                   PSLFVSTPQSMAHPCGGTPTYPESQIFFPTIHERPVSFSPPPTCPPKVAISQRRKSTSF
FT                   LEAQTHHFQPLLRTVGQSLLPPGGSPTNWTPEAVVMLGTTASRVTGESCEIQVHPMFEP
FT                   SQVYSDYRPGLVLPEEAHYFIPQEAVYVAGVHYQARVAEQYEGIPYNSSVLSSPMKQIP
FT                   EQKPVQGGPTSSSVFEFPSGQAFLVGHLQNLRLDSGLGPGSPLSSISAPISTDATRLKF
FT                   HPVFVPHSAPAVLTHNNESRSNCVFEFHVHTPSSSSGEGGGILPQRVYRNRQVAVDLNQ
FT                   EELPPQSVGLHGYLQPVTEEKHNYHAPELTVSVVEPIGQNWPIGSPEYSSDSSQITSSD
FT                   PSDFQSPPPTGGAAAPFGSDVSMPFIHLPQTVLQESPLFFCFPQGTTSQQVLTASFSSG
FT                   GSALHPQAQGQSQGQPSSSSLTGVSSSQPIQHPQQQQGIQQTAPPQQTVQYSLSQTSTS
FT                   SEATTAQPVSQPQAPQVLPQVSAGKQ (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_040268"
FT   VAR_SEQ         740
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9205841"
FT                   /id="VSP_040269"
FT   VAR_SEQ         792..1037
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9205841"
FT                   /id="VSP_050638"
FT   VAR_SEQ         792..944
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_040270"
FT   VAR_SEQ         2215
FT                   /note="G -> GCAKFNCASEQVTFKPGGRRTRFLRKMVKKVCPCNQLCR (in
FT                   isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:22701532"
FT                   /id="VSP_053767"
FT   VARIANT         141
FT                   /note="A -> T (in dbSNP:rs11554421)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041309"
FT   VARIANT         149
FT                   /note="A -> V (in dbSNP:rs34880640)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041310"
FT   VARIANT         419
FT                   /note="E -> Q (in a breast pleomorphic lobular carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041311"
FT   VARIANT         509
FT                   /note="I -> T (in dbSNP:rs34728563)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041312"
FT   VARIANT         527
FT                   /note="D -> G (in dbSNP:rs34408667)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041313"
FT   VARIANT         665
FT                   /note="T -> I (in dbSNP:rs2286007)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_019992"
FT   VARIANT         674
FT                   /note="T -> A (in dbSNP:rs11833299)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041314"
FT   VARIANT         823
FT                   /note="H -> R (in dbSNP:rs56015776)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041315"
FT   VARIANT         1056
FT                   /note="T -> P (in dbSNP:rs956868)"
FT                   /evidence="ECO:0000269|PubMed:11571656,
FT                   ECO:0000269|PubMed:9205841, ECO:0000269|Ref.3"
FT                   /id="VAR_059033"
FT   VARIANT         1199
FT                   /note="E -> G (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035640"
FT   VARIANT         1506
FT                   /note="C -> S (in dbSNP:rs7955371)"
FT                   /evidence="ECO:0000269|PubMed:11571656,
FT                   ECO:0000269|PubMed:9205841, ECO:0000269|Ref.3"
FT                   /id="VAR_059034"
FT   VARIANT         1546
FT                   /note="A -> V (in dbSNP:rs56351358)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041316"
FT   VARIANT         1799
FT                   /note="Q -> E (in breast cancer samples; infiltrating
FT                   ductal carcinoma; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_035641"
FT   VARIANT         1808
FT                   /note="M -> I (in dbSNP:rs12828016)"
FT                   /evidence="ECO:0000269|PubMed:11571656,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3"
FT                   /id="VAR_041317"
FT   VARIANT         1823
FT                   /note="P -> L (in dbSNP:rs17755373)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041318"
FT   VARIANT         1957
FT                   /note="R -> H (in dbSNP:rs36083875)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041319"
FT   VARIANT         2190
FT                   /note="S -> C (in a breast pleomorphic lobular carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041320"
FT   VARIANT         2362
FT                   /note="F -> L (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041321"
FT   VARIANT         2380
FT                   /note="R -> W (in dbSNP:rs56262445)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041322"
FT   CONFLICT        164
FT                   /note="R -> S (in Ref. 8; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1836
FT                   /note="Missing (in Ref. 6; BAA20802)"
FT                   /evidence="ECO:0000305"
FT   STRAND          211..214
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   STRAND          216..218
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   STRAND          220..228
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   STRAND          231..240
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   TURN            241..244
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   STRAND          245..252
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   HELIX           266..273
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   STRAND          283..288
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   STRAND          291..295
FT                   /evidence="ECO:0007829|PDB:5WDY"
FT   STRAND          297..302
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   HELIX           309..316
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   HELIX           321..340
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   STRAND          341..343
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   HELIX           352..354
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   STRAND          355..358
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   TURN            359..362
FT                   /evidence="ECO:0007829|PDB:5WE8"
FT   STRAND          364..366
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   HELIX           369..371
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   STRAND          377..380
FT                   /evidence="ECO:0007829|PDB:5WE8"
FT   HELIX           392..396
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   HELIX           402..417
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   TURN            421..424
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   HELIX           428..435
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   TURN            436..438
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   HELIX           442..446
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   HELIX           450..459
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   HELIX           464..466
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   HELIX           470..474
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   HELIX           477..481
FT                   /evidence="ECO:0007829|PDB:4PWN"
FT   STRAND          1248..1251
FT                   /evidence="ECO:0007829|PDB:6FBK"
FT   STRAND          1257..1261
FT                   /evidence="ECO:0007829|PDB:6FBK"
SQ   SEQUENCE   2382 AA;  250794 MW;  426785F98A452A0A CRC64;
     MSGGAAEKQS STPGSLFLSP PAPAPKNGSS SDSSVGEKLG AAAADAVTGR TEEYRRRRHT
     MDKDSRGAAA TTTTTEHRFF RRSVICDSNA TALELPGLPL SLPQPSIPAA VPQSAPPEPH
     REETVTATAT SQVAQQPPAA AAPGEQAVAG PAPSTVPSST SKDRPVSQPS LVGSKEEPPP
     ARSGSGGGSA KEPQEERSQQ QDDIEELETK AVGMSNDGRF LKFDIEIGRG SFKTVYKGLD
     TETTVEVAWC ELQDRKLTKS ERQRFKEEAE MLKGLQHPNI VRFYDSWEST VKGKKCIVLV
     TELMTSGTLK TYLKRFKVMK IKVLRSWCRQ ILKGLQFLHT RTPPIIHRDL KCDNIFITGP
     TGSVKIGDLG LATLKRASFA KSVIGTPEFM APEMYEEKYD ESVDVYAFGM CMLEMATSEY
     PYSECQNAAQ IYRRVTSGVK PASFDKVAIP EVKEIIEGCI RQNKDERYSI KDLLNHAFFQ
     EETGVRVELA EEDDGEKIAI KLWLRIEDIK KLKGKYKDNE AIEFSFDLER DVPEDVAQEM
     VESGYVCEGD HKTMAKAIKD RVSLIKRKRE QRQLVREEQE KKKQEESSLK QQVEQSSASQ
     TGIKQLPSAS TGIPTASTTS ASVSTQVEPE EPEADQHQQL QYQQPSISVL SDGTVDSGQG
     SSVFTESRVS SQQTVSYGSQ HEQAHSTGTV PGHIPSTVQA QSQPHGVYPP SSVAQGQSQG
     QPSSSSLTGV SSSQPIQHPQ QQQGIQQTAP PQQTVQYSLS QTSTSSEATT AQPVSQPQAP
     QVLPQVSAGK QLPVSQPVPT IQGEPQIPVA TQPSVVPVHS GAHFLPVGQP LPTPLLPQYP
     VSQIPISTPH VSTAQTGFSS LPITMAAGIT QPLLTLASSA TTAAIPGVST VVPSQLPTLL
     QPVTQLPSQV HPQLLQPAVQ SMGIPANLGQ AAEVPLSSGD VLYQGFPPRL PPQYPGDSNI
     APSSNVASVC IHSTVLSPPM PTEVLATPGY FPTVVQPYVE SNLLVPMGGV GGQVQVSQPG
     GSLAQAPTTS SQQAVLESTQ GVSQVAPAEP VAVAQTQATQ PTTLASSVDS AHSDVASGMS
     DGNENVPSSS GRHEGRTTKR HYRKSVRSRS RHEKTSRPKL RILNVSNKGD RVVECQLETH
     NRKMVTFKFD LDGDNPEEIA TIMVNNDFIL AIERESFVDQ VREIIEKADE MLSEDVSVEP
     EGDQGLESLQ GKDDYGFSGS QKLEGEFKQP IPASSMPQQI GIPTSSLTQV VHSAGRRFIV
     SPVPESRLRE SKVFPSEITD TVAASTAQSP GMNLSHSASS LSLQQAFSEL RRAQMTEGPN
     TAPPNFSHTG PTFPVVPPFL SSIAGVPTTA AATAPVPATS SPPNDISTSV IQSEVTVPTE
     EGIAGVATST GVVTSGGLPI PPVSESPVLS SVVSSITIPA VVSISTTSPS LQVPTSTSEI
     VVSSTALYPS VTVSATSASA GGSTATPGPK PPAVVSQQAA GSTTVGATLT SVSTTTSFPS
     TASQLCIQLS SSTSTPTLAE TVVVSAHSLD KTSHSSTTGL AFSLSAPSSS SSPGAGVSSY
     ISQPGGLHPL VIPSVIASTP ILPQAAGPTS TPLLPQVPSI PPLVQPVANV PAVQQTLIHS
     QPQPALLPNQ PHTHCPEVDS DTQPKAPGID DIKTLEEKLR SLFSEHSSSG AQHASVSLET
     SLVIESTVTP GIPTTAVAPS KLLTSTTSTC LPPTNLPLGT VALPVTPVVT PGQVSTPVST
     TTSGVKPGTA PSKPPLTKAP VLPVGTELPA GTLPSEQLPP FPGPSLTQSQ QPLEDLDAQL
     RRTLSPEMIT VTSAVGPVSM AAPTAITEAG TQPQKGVSQV KEGPVLATSS GAGVFKMGRF
     QVSVAADGAQ KEGKNKSEDA KSVHFESSTS ESSVLSSSSP ESTLVKPEPN GITIPGISSD
     VPESAHKTTA SEAKSDTGQP TKVGRFQVTT TANKVGRFSV SKTEDKITDT KKEGPVASPP
     FMDLEQAVLP AVIPKKEKPE LSEPSHLNGP SSDPEAAFLS RDVDDGSGSP HSPHQLSSKS
     LPSQNLSQSL SNSFNSSYMS SDNESDIEDE DLKLELRRLR DKHLKEIQDL QSRQKHEIES
     LYTKLGKVPP AVIIPPAAPL SGRRRRPTKS KGSKSSRSSS LGNKSPQLSG NLSGQSAASV
     LHPQQTLHPP GNIPESGQNQ LLQPLKPSPS SDNLYSAFTS DGAISVPSLS APGQGTSSTN
     TVGATVNSQA AQAQPPAMTS SRKGTFTDDL HKLVDNWARD AMNLSGRRGS KGHMNYEGPG
     MARKFSAPGQ LCISMTSNLG GSAPISAASA TSLGHFTKSM CPPQQYGFPA TPFGAQWSGT
     GGPAPQPLGQ FQPVGTASLQ NFNISNLQKS ISNPPGSNLR TT
//
